Astrazeneca Pharma India Ltd (ASTRAZEN) — Announcement | 2 September 2026
AstraZeneca Pharma India disclosed its ESG rating of 64 from Crisil ESG Ratings, based on FY2026 public data, without company engagement or endorsement, highlighting independent assessment of environmental, social, and governance practices.
About Astrazeneca Pharma India Ltd (ASTRAZEN)
Healthcare · Pharmaceuticals · Listed on BSE
📡 Get AI alerts when ASTRAZEN files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track ASTRAZEN — Free💡 Ask AI about this filing
📊 More ASTRAZEN filings
- 🔴 Announcement — 18 September 2026AstraZeneca Pharma India disclosed a penalty of Rs.1.88 lakh imposed by the Registrar of Companies f...
- Announcement — 15 September 2026AstraZeneca Pharma India Ltd announced that its trading window will close on September 16, 2026, to ...
- 🔴 Announcement — 15 September 2026AstraZeneca Pharma India announced the resignation of Dr. Sandeep Arora, Director of Medical Affairs...
- Announcement — 25 August 2026AstraZeneca Pharma India Limited disclosed that the Delhi High Court stayed an NPPA demand notice al...
- Announcement — 24 August 2026AstraZeneca Pharma India Limited disclosed its ESG rating of 57 from Crisil ESG Ratings, based on pu...
🔥 Also filed on 2 September 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when ASTRAZEN files new disclosures
Track ASTRAZEN filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track ASTRAZEN — FreeFree account · 2 AI queries/day